Biotechnology firm ZymoGenetics of Seattle, Washington, is cutting 129 research and development positions in cancer research. Susan Specht, spokeswoman for the company, says that ZymoGenetics will now concentrate on immunology. “All oncology research projects have been cancelled,” she says. She adds that some R&D positions in cancer research will be transferred to immunology research but could not specify how many. The company, which now employs 349, expects to save US$30 million a year.